Discover how moderate-to-vigorous physical activity can reduce exacerbations and corticosteroid use in COPD patients on dual ...

Discover the latest insights from the TOReTO study on COPD management: Dual bronchodilator therapy has been shown to reduce exacerbations, with varying efficacy between current and former smokers.

Background: In contrast to asthma, the indication for bronchodilators prior to bronchoscopy in patients with COPD has not been properly investigated. We therefore performed a randomized ...

Ipratropium (brand name, Atrovent HFA; Boehringer-Ingelheim) is a short-acting bronchodilator. It is used to prevent wheezing, shortness of breath, coughing, and chest tightness in people with COPD.

Dubai: The first biological treatment for chronic obstructive pulmonary disease (COPD), now available in the UAE, offers new ...

Chronic obstructive pulmonary disease (COPD), an irreversible form of lung disease, is treated with prescription drugs, lifestyle changes, rehabilitation therapies, and surgery in certain cases. The ...

Formoterol (brand names Perforomist, Foradil) is a bronchodilator in a class of medications called long-acting beta agonists (LABAs). It is used to control wheezing, shortness of breath, coughing and ...

Current guidelines recommend use of one or more long-acting inhaled bronchodilators for patients with moderate, severe, or very severe COPD. However, the initial choice of long-acting inhaled ...

American Thoracic Society guidelines recommend that people with moderate or severe COPD who experience shortness of breath and/or exercise intolerance receive a combination of two different types of ...

What is the landscape like for COPD treatments at the moment? Today you have two types of bronchodilators. Inhaled drugs that open the airways – beta 2 agonists and antimuscarinics – were ...

Study Aim To describe treatment pathways 5 years prior to initiation of dual bronchodilator therapy (LABA+LAMA) or on triple inhaled therapy (ICS+LABA+LAMA), in single or separate inhalers, in ...

A new study suggests COPD patients experience improved lung function and breathlessness after direct switch from long-acting bronchodilators or steroid containing combination therapies to ...